biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Midatech's Glioblastoma Drug and xB3 Synergy:

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jan 15, 2023 6:29pm

78 Views

Post# 35224523

RE:RE:RE:RE:RE:RE:RE:Midatech's Glioblastoma Drug and xB3 Synergy:

Correct, poof. And CED is intracranial. What is your understanding of diffuse target engagement with convection-enhanced delivery?

Does CED have prophylactic value for diffuse tumours or is it necessary to wait for larger solid tumours grow before CED becomes an option?

And why would intracranial delivery be used when a simple injection of an xB3-Drug would deliver its payload throughout the CNS rather than locally as we see with CED?

jd

<< Previous

Bullboard Posts

Next >>

Three micro-cap stocks on an upswing worth riding